Promotional Tracking Factor XIa Inhibitors for NVAF - Cardiologists' Perspectives Key Findings •Eliquis is currently the top choice for stroke prevention in NVAF, being used in 56% of patients, followed by Xarelto at 26% • Mirroring usage, 77% of cardiologists perceive Eliquis as performing
